Next Article in Journal
Evaluation of a Clinical Index as a Predictive Tool for Primary Ciliary Dyskinesia
Previous Article in Journal
Active Herpes Zoster Mimicking Worsening of Axillary Lymph Node Metastases of Breast Cancer after Chemotherapy on 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography
Article

uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study

1
Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
2
Cluster for Molecular Imaging, Department of Biomedical Sciences and Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark
3
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
*
Author to whom correspondence should be addressed.
Academic Editor: Alexander Haug
Diagnostics 2021, 11(6), 1087; https://doi.org/10.3390/diagnostics11061087
Received: 8 May 2021 / Revised: 6 June 2021 / Accepted: 8 June 2021 / Published: 14 June 2021
(This article belongs to the Section Medical Imaging)
The aim of this Phase II study was to investigate the potential for response assessment and prognostication of positron emission tomography (PET) using the ligand 68Ga-NOTA-AE105 targeting the urokinase-type plasminogen activator receptor (uPAR) in patients receiving Radium-223-dichloride therapy (223RaCl2). A combined whole-body uPAR PET and computed tomography (CT) was performed before initiation of 223RaCl2 and after two cycles of therapy. Standardized uptake value (SUV) in selected bone metastases was measured and the lesion with the highest SUVmax was considered the index lesion. Clinical outcomes were overall survival (OS), radiographic progression free survival (rPFS) and occurrence of symptomatic skeletal event (SSE). A total of 17 patients were included and 14 patients completed both baseline and follow-up uPAR-PET/CT. Baseline SUVmax of the index lesion was associated with OS; hazard ratio 2.51 (95% CI: 1.01–6.28, p = 0.05) per unit increase in SUVmax. No association between changes in SUVmax from baseline to follow-up and OS, progression during therapy, or rPFS was found. Baseline SUVmax was a significant predictor of SSE with receiver operating characteristics (ROC) area under the curve (AUC) = 0.81 (95% CI: 0.58–1.00, p = 0.034). A cut-off for tumor SUVmax could be established with an odds ratio of 14.0 (95% CI: 1.14–172.6, p = 0.023) for occurrence of SSE within 12 months. Although based on a small number of patients, uPAR-PET SUVmax in bone metastases was predictive for OS and risk of SSE in mCRPC patients receiving 223RaCl2. However, a relatively low uptake of the uPAR ligand in bone metastases impedes visual evaluation and requires another modality for lesion delineation. View Full-Text
Keywords: urokinase-type plasminogen activator receptor (uPAR); prostate cancer; PET; Radium-223 therapy urokinase-type plasminogen activator receptor (uPAR); prostate cancer; PET; Radium-223 therapy
Show Figures

Figure 1

MDPI and ACS Style

Fosbøl, M.Ø.; Mortensen, J.; Petersen, P.M.; Loft, A.; Madsen, J.; Kjaer, A. uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study. Diagnostics 2021, 11, 1087. https://doi.org/10.3390/diagnostics11061087

AMA Style

Fosbøl MØ, Mortensen J, Petersen PM, Loft A, Madsen J, Kjaer A. uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study. Diagnostics. 2021; 11(6):1087. https://doi.org/10.3390/diagnostics11061087

Chicago/Turabian Style

Fosbøl, Marie Ø., Jann Mortensen, Peter M. Petersen, Annika Loft, Jacob Madsen, and Andreas Kjaer. 2021. "uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study" Diagnostics 11, no. 6: 1087. https://doi.org/10.3390/diagnostics11061087

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop